The Pharma Brand Planners’ Blog: Part 1

At this time of year, I’m often contacted by global franchise or brand leaders, sometimes in a bit of a panic, wondering how to go about developing the best possible ... And do you have a healthy sense of innovation and independence of spirit to tackle

Novo Nordisk and Gilead join forces in NASH

Investing further in NASH is also vital for Gilead, where new CEO Daniel O'Day needs to find new revenue streams to replace its declining hepatitis C franchise.

Vertex: a vision of treating all CF patients worldwide draws closer

The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

Pfizer gets EU nod for Tagrisso rival Vizimpro

For Pfizer, the Vizimpro approval is another pillar in its bid to rebuild its oncology franchise that has been hit hard by competition to Xalkori (crizotinib) for ALK-positive NSCLC from

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]